Amarin Corp Plcuk (AMRN) Change in Receivables (2013 - 2026)
Amarin Corp Plcuk (AMRN) reported Change in Receivables of -$18.8 million for Q1 2026, down 20.82% year-over-year from -$23.7 million in Q1 2025, and down 3837.32% quarter-over-quarter from -$477000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Change in Receivables (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 14 years of Change in Receivables data on file, last reported at -$18.8 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$18.8 million, down 20.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 114.52% YoY), and the FY2025 annual result was $4.6 million, up 140.35% from the prior year.
- Change in Receivables fell to -$18.8 million in Q1 2026 per AMRN's latest filing, from -$477000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $33.7 million in Q2 2022 and troughed at -$53.4 million in Q1 2022.
- A 5-year average of -$3.3 million and a median of -$330000.0 in 2023 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 175.05% in 2024 and fell as far as 3248.18% in 2024.
- A 5-year view of Change in Receivables shows it stood at $7.6 million in 2022, then jumped by 46.67% to $11.2 million in 2023, then slipped by 13.67% to $9.6 million in 2024, then tumbled by 104.95% to -$477000.0 in 2025, then slumped by 3837.32% to -$18.8 million in 2026.
- Business Quant data shows AMRN's Change in Receivables at -$18.8 million in Q1 2026, -$477000.0 in Q4 2025, and $8.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 595.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -87.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.69 Bn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | -18.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.78 Mn |
| Mar 31, 2026 | -18.78 Mn |
| Dec 31, 2025 | -477,000.00 |
| Dec 31, 2025 | -477,000.00 |
| Sep 30, 2025 | 8.18 Mn |
| Sep 30, 2025 | 8.18 Mn |
| Jun 30, 2025 | 12.40 Mn |
| Jun 30, 2025 | 12.40 Mn |
| Mar 31, 2025 | -15.55 Mn |
| Mar 31, 2025 | -15.55 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Jun 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 7.89 Mn |
| Mar 31, 2024 | -17.76 Mn |
| Mar 31, 2024 | -17.76 Mn |
| Dec 31, 2023 | 11.16 Mn |
| Dec 31, 2023 | 11.16 Mn |